Chronic Granulomatous Disease Market Research Report: By Diagnosis (Neutrophil Function Tests, Genetic Testing, Others), by Treatment (Infection Management, Interferon-gamma, Stem Cell Transplantation), by End-User (Hospitals, Others) - Forecast Till 2027
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6447
Key players
Pfizer, Inc., InterMune, Inc., Novartis AG, Lonza Group, GlaxoSmithKline Plc, Eli Lilly and Company, Janssen Pharmaceuticals, Merck KGaA, Osiris Therapeutics, Inc, JCR Pharmaceuticals Co., Ltd., Maxcyte Inc., and Horizon Pharma Plc are some prominent player in the market.
Segmentation
The global chronic granulomatous disease market has been segmented into type, diagnosis, treatment, and end user.
The market, on the basis of type, is segmented into X-linked chronic granulomatous disease and autosomal recessive chronic granulomatous disease.
The market, by diagnosis, has been segmented into neutrophil function tests, genetic testing, prenatal testing, and others.
The market, by treatment, has been segmented into infection management, interferon-gamma, stem cell transplantation, and others. The infection management segment has been further segmented into trimethoprim, sulfamethoxazole, itraconazole, and others.
On the basis of end user, the market has been segmented into hospitals, clinical laboratories, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The chronic granulomatous disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European chronic granulomatous disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The chronic granulomatous disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The chronic granulomatous disease market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global chronic granulomatous disease market owing to a well-developed healthcare sector, rising prevalence of rare diseases, steady growing occurrence of chronic granulomatous disease (CGD), and relatively large number of research and development activities. According to an article published by the National Center for Biotechnology Information (NCBI) in 2017, the incidence of CGD in the US is around 1 in 200,000 to 1 in 250,000 births.
Europe is expected to hold the second largest position in the chronic granulomatous disease market. The market growth in this region is attributed to the rising prevalence of rare diseases and increasing research and development activities. According to the Eurostat, the gross domestic expenditure (GERD) on R&D was EUR 303 billion in the year 2016.
The chronic granulomatous disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to continuously developing economies, rising prevalence of rare diseases, growing awareness about rare diseases, and increasing government funding for the healthcare sector.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector, and growing prevalence of CGD and growing government initiatives for the healthcare sector. As per to an article published in the National Center for Biotechnology Information (NCBI) in 2017, the incidence of CGD is 1 in 70,000 in the Israeli Arab population.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/chronic-granulomatous-disease-market-6447
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
